Baylor College of Medicine

Milestone Scientific Commences Sales of CompuFlo®  Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures

Retrieved on: 
Friday, December 8, 2023
Baylor University, MD Anderson Cancer Center, Baylor College of Medicine, Cleveland Clinic, Trauma, Risk, UTHealth School of Dentistry, American Epilepsy Society, Physician, Injection, Electricity, Spinal cord, Hospital, MD, UTMB, Congress, University, Chronic pain, Nursing, Safety, MLSS

ROSELAND, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported it has commenced commercial sales of CompuFlo® disposables for use in neurostimulation spinal cord stimulator implantation procedures at the University of Texas Medical Branch (UTMB) Health Clear Lake Campus Hospital, expanding use of CompuFlo® within the institution beyond the labor and delivery department and training for residents in epidural needle placement and verification.

Key Points: 
  • A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.
  • An estimated 60,000 spinal cord stimulators are implanted each year.
  • Approval and adoption of the technology for neurostimulation spinal cord stimulator implantation follows a successful evaluation process by Dr. Patrick Karas, MD, a full-time faculty neurosurgeon at UTMB, operating at both the Galveston and Clear Lake campuses.
  • Dr. Karas completed 10 cases using the CompuFlo Epidural system, in which he reported 100% success and no complications.

CARGO Therapeutics Announces Scientific Advisory Board

Retrieved on: 
Wednesday, December 6, 2023
Associate, Baylor University, Baylor College of Medicine, Hospital, Division, Research, Investment company, Massachusetts General Hospital, MD, Doctor of Philosophy, SAB, SAN, Therapy, Cancer, CD2, Health, Section, Dana–Farber Cancer Institute, University, Hematology, Faculty, MBBS, Royal North Shore Hospital, Patient, Boston, Harvard Medical School, MGH, Medical school, CD22, Nursing

SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
  • The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies.
  • “The SAB stands out by bringing together several highly accomplished translational investigators each with CAR T-cell experience that bridges both the laboratory and the clinic,” said Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair.
  • “They are uniquely suited to advise CARGO on their scientific goals and directions that will lead to better outcomes for patients.”
    Members of the CARGO Scientific Advisory Board are listed below; full bios are available on the CARGO website .

Seth L. Matarasso, MD, Begins ASDS / ASDSA Presidency

Retrieved on: 
Monday, November 27, 2023
Mentorship, Treasurer, Policy, Baylor College of Medicine, Archive, Physician, ASDS, Hope, Evidence-based medicine, Strategic planning, MD, Society, Samuel, American Academy, University, Human, Mount Sinai School, Publication, Journal, Strategy, Clinical professor, Communication

Reimagining the future by fostering member engagement in and proactively reinforcing patient safety with those in a position to determine policy on the practice of medicine.

Key Points: 
  • Reimagining the future by fostering member engagement in and proactively reinforcing patient safety with those in a position to determine policy on the practice of medicine.
  • Embracing change and hope by implementing a new strategic plan and confirming a new Executive Director.
  • Enhancing and evolving members’ unified communication as credible medical sources, educating the public, medical peers and legislators on the scope of dermatologic surgeons’ expertise.
  • “To serve as the President of the ASDS and ASDSA is one of the most significant honors of my professional career; it is humbling and a privilege,” said Dr. Matarasso during his first presidential address.

Guthrie Ophthalmologist Named Catholic Doctor of the Year

Retrieved on: 
Friday, November 17, 2023
Difference, African, Glioblastoma, Baylor University, Catholic Church, Patient, Baylor College of Medicine, Well, Friends, University, Glasses, Diagnosis, Primary tumor, Family, Health professional, Sport, Brain, Maryknoll Society, Nursing, Medical device

In 1988, she went on her first medical mission trip to a Catholic Mission Hospital in Abak, Nigeria.

Key Points: 
  • In 1988, she went on her first medical mission trip to a Catholic Mission Hospital in Abak, Nigeria.
  • In 2006, Dr. Schanzer and her husband, at the invitation of local Archbishop Joseph Ganda, established Southern Eye Clinic in Serabu, Sierra Leone.
  • Today, Southern Eye Clinic of Serabu is open year-round, providing diagnostic examinations, medicines, eyeglasses, and modern eye surgery free of charge to all patients.
  • Dr. Schanzer and her husband are grateful for their deep faith and the strong worldwide support of family and friends.

Vascular Perfusion Solutions Receives Grant from Southwest-Midwest National Pediatric Device Innovation Consortium To Develop Portable Pediatric Heart Transplant Preservation Device

Retrieved on: 
Thursday, December 7, 2023
Surgery, Medical Devices, Cardiology, Philanthropy, Biotechnology, Health, Fund Raising, Other Philanthropy, Foundation, TCH, Infant, Engineering, Cardiomyopathy, Transplant, VPS, Perfusion, Patient, FDA, Baylor College of Medicine, Science, Ventricular septal defect, Standard of care, MBA, MD, Doctor of Philosophy, Heart transplantation, P50, BCM, Life, Pharmaceutical industry, Dentistry, Medical device

Vascular Perfusion Solutions (VPS), Inc. , is a San Antonio based medical device startup company focused on developing novel prolonged organ preservation technologies prior to transplantation, has received a $25,000 grant from the Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC) .

Key Points: 
  • Vascular Perfusion Solutions (VPS), Inc. , is a San Antonio based medical device startup company focused on developing novel prolonged organ preservation technologies prior to transplantation, has received a $25,000 grant from the Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC) .
  • VPS will use the grant to advance its current VP.S ENCORE® cardiac preservation technology into a portable pediatric device.
  • Pediatric heart failure presents unique challenges compared to its adult counterpart, stemming from diverse causes such as congenital heart defects and cardiomyopathy.
  • In 2021, 1,146 pediatric heart transplant candidates awaited transplantation, with over 40 percent enduring waits of a year or more.

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

Retrieved on: 
Wednesday, December 6, 2023
Oncology, Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, Human body, Baylor University, Honours degree, Patient, Multimedia, McGill University, Baylor College of Medicine, Neoplasm, Physiology, Growth, Texas Medical Center, Business, CBO, Lazard, Pharmaceutical industry, Northwestern University

Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced that Rizwan Velji has been appointed Chief Business Officer (CBO).

Key Points: 
  • Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced that Rizwan Velji has been appointed Chief Business Officer (CBO).
  • View the full release here: https://www.businesswire.com/news/home/20231206761602/en/
    Rizwan Velji has joined Alentis Therapeutics as Chief Business Officer (Photo: Alentis Therapeutics)
    “Rizwan possesses an incredible depth of experience in corporate and financial strategy for biotech companies,” said Roberto Iacone, Chief Executive Officer of Alentis.
  • Rizwan Velji said, “I am very excited to be joining Alentis at this critical juncture in their life cycle, as they rapidly advance their lead candidates through early clinical development.
  • My goal is to support the growth and evolution of the company further securing Alentis’ leading position in Claudin-1 biology.

Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome

Retrieved on: 
Thursday, November 30, 2023
Health, Neurology, Surgery, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Courage, Associate, Brain, Research, Safety, GMP, Food, Hope, Pediatrics, Toxicity, Baylor University, Clinical trial, MECP2, DSM-IV codes, Patient, FDA, Baylor College of Medicine, Data monitoring committee, McMinn, Toxic leukoencephalopathy, Epilepsy surgery, Rett syndrome, ICV, Orphan, Female, Inc., Șaeș, Neurosurgery, Construct, AAV, Hospital, Spinal cord, Neurodevelopmental disorder, Pharmaceutical industry, Vaccine

NGN-401 is an investigational adeno-associated virus (AAV) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize the therapeutic activity while averting transgene overexpression toxicities.

Key Points: 
  • NGN-401 is an investigational adeno-associated virus (AAV) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize the therapeutic activity while averting transgene overexpression toxicities.
  • NGN-401 delivers the full-length human methyl cytosine binding protein 2 (MECP2) gene, providing an optimal gene replacement approach.
  • In non-clinical studies with NGN-401 at clinically relevant doses, cardinal features of Rett syndrome were ameliorated, and no overexpression toxicity was observed.
  • Your resilience, courage, and support not only contribute to the progress of this research, but also inspire hope within the entire Rett syndrome community.

Novosound Expands Healthcare and Wearable Ultrasound Operations in US

Retrieved on: 
Tuesday, November 28, 2023
Health, Medical Devices, Technology, Hospitals, Health Technology, Audio, Video, Wearables, Mobile Technology, CES, Texas Medical Center, Pump, Baylor University, DirectSound, Multimedia, Hughes, Baylor College of Medicine, UK Space Agency, Partnership, Axiom Space, Vital signs, Medical imaging, Medical device

Scottish startup Novosound has expanded its healthcare and wireless wearable ultrasound operations in the US.

Key Points: 
  • Scottish startup Novosound has expanded its healthcare and wireless wearable ultrasound operations in the US.
  • View the full release here: https://www.businesswire.com/news/home/20231128490755/en/
    Novosound's wearable ultrasound technology set to advance vital signs monitoring.
  • Overall, we’re demonstrating that we’re at the forefront of ultrasound sensor technology, and our clients are helping us achieve our vision, which we describe as ‘Ultrasound.
  • Everywhere.’”
    - Novosound will be featuring at Pumps & Pipes in Houston on December 4, and CES 2024 9-12 January.

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, MTV: TRL Christmas, Malignancy, Safety, Fasting, Heart, Risk, AHA, Hypertriglyceridemia, TGS, Apolipoprotein B, Serum, Cleveland Clinic, Baylor College of Medicine, APOC3, American Heart Association, Dyslipidemia, MD, Triglyceride, Doctor of Philosophy, ASCVD, Arrowhead Pharmaceuticals, ANGPTL3, Moyamoya disease, Pharmaceutical industry, Shipbuilding, Medical device, Arrowhead, Medicine, Patient

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.
  • Despite potent LDL-C lowering therapies, residual ASCVD risk persists due in part to high levels of atherogenic TRLs.
  • At 24 weeks, plozasiran durably decreased serum APOC3 to -79%, TGs to -74%, and remnant cholesterol to -63%, while increasing HDL-cholesterol to +68%.
  • Serious TEAEs were not related to plozasiran and were resolved without sequelae, except two subjects with malignancies.

Maya Barsky, MD, MSCI Joins the Center for Advanced Reproductive Services as a Lead Physician

Retrieved on: 
Tuesday, December 12, 2023
REI, Assistant, Brown University, Research, Fertility, Baylor University, University, Patient, Pulsus Group, Baylor College of Medicine, American College, ACOG, ASRM, PCOS, Reproductive medicine, Fertility preservation, Society, Meigs's syndrome, Ovarian reserve, Birth control, Infertility, Gynaecology

FARMINGTON, Conn., Dec. 12, 2023 /PRNewswire/ -- The Center for Advanced Reproductive Services, one of the leading family building programs in the country, announced Dr. Maya Barsky, reproductive endocrinologist, has joined as Lead Physician and Assistant Professor in the Department of Ob/Gyn at UConn School of Medicine.

Key Points: 
  • FARMINGTON, Conn., Dec. 12, 2023 /PRNewswire/ -- The Center for Advanced Reproductive Services, one of the leading family building programs in the country, announced Dr. Maya Barsky, reproductive endocrinologist, has joined as Lead Physician and Assistant Professor in the Department of Ob/Gyn at UConn School of Medicine.
  • "I am very fortunate to be a part of such a respected and successful program as the Center for Advanced Reproductive Services."
  • Dr. Barsky is available to connect with patients via telehealth appointments effective immediately, with in-person appointments beginning in January 2024.
  • Prior to joining The Center for Advanced Reproductive Services, she was part of a private fertility practice in Austin, TX for several years.